Schizophrenia
Conditions
Brief summary
The purpose of this study was to assess the safety and tolerability of injections of RBP-7000 in subjects with stable schizophrenia
Detailed description
This was an open-label, single-center, Phase 1, single ascending dose study, designed to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of a single SC injection of low, medium and high doses of RBP-7000 in subjects with clinically stable schizophrenia who were not taking risperidone. The design was a sequential cohort with treatment initiated in 3 cohorts after safety and tolerability at a lower dose were confirmed. Eligible subjects received a single oral test dose of 0.25mg risperidone under medical supervision. Subjects who continued to be eligible were admitted to a residential unit for approximately 14 days, and received a single dose of RBP-7000. Subjects were discharged on Day 15 and returned to the clinical site weekly for approximately 10 weeks.
Interventions
DRUGRBP-7000
Sequential dosing of each cohort
DRUGrisperidone
All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.
Sponsors
Indivior Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Subjects with confirmed diagnosis of paranoid, residual, or undifferentiated schizophrenia in a documented letter from the subject's psychiatrist or primary care provider. * Clinically stable subjects (subjects whom the PI established by medical record or by history from the subject and at least 1 reliable informant, that the subject had been clinically stable for at least 60 days without hospitalization). * Subjects with body mass index (BMI) between 18 and 33 kg/m2 and weight of at least 49.9 kg. * Subjects who gave written informed consent.
Exclusion criteria
* Subjects taking any risperidone product within the last 60 days prior to study screening. * Subjects with a history of cancer (excluding resected basal cell or squamous cell carcinoma of the skin) unless they had been disease free for ≥ 5 years. * Subjects with another active medical condition or organ disease that could have either compromised subject safety or interfered with the safety and/or outcome evaluation of the study drug. This included, but was not limited to the following abnormalities: total bilirubin \> 2.5 mg/dL (51 μmol/L), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 × the upper limit of normal (ULN) or clinically significant serum creatinine \> 2 x ULN, international normalized ratio (INR) ≥ 2.0. Other excluded medical conditions included, but were not limited to: history of heart attack, brain injury, low blood pressure, and clinically significant irregular heartbeat as interpreted by the PI. * Subjects who were known to have acquired immune deficiency syndrome or to be human immunodeficiency virus (HIV) positive. * Subjects with evidence or history of significant hepatic disorder, including acute or chronic hepatitis B and acute hepatitis C. Subjects with hepatitis C antibody and liver functions ≤ 1.5 times the ULN could be included in the study. * Subjects with known diagnosis of type 1 or 2 diabetes or subjects with a clinically significant abnormal hemoglobin A1c (HbA1c) at screening as interpreted by the PI. * Subjects with clinically significant comorbidities that could affect near-term survival. * Subjects treated with any investigational drug within the last 30 days prior to study screening. * Subjects with significant traumatic injury, major surgery, or open biopsy within the last 4 weeks prior to study screening. * Subjects receiving opioid or opioid-containing analgesics within the last 30 days prior to study screening. * Subjects consuming \> 1 alcoholic drink per day within the last 30 days prior to study screening (defined as 1 oz. of 80 proof spirits, 12 oz. of beer, or 4 oz. of wine). * Subjects with prior allergic reactions, sensitivities, or other known contraindications to any component of RBP-7000 (i.e., risperidone, poly \[DL-lactide-co-glycolide\], or N-methylpyrrolidone). * Subjects with other concurrent uncontrolled illness that may have interfered with the ability to participate in the study. * Women with a positive pregnancy test at screening. Women of childbearing potential, who were pregnant or lactating, seeking pregnancy, or failing to take adequate contraceptive precautions (e.g., an oral or injectable contraceptive, an approved hormonal implant or topical patch, or an intrauterine device). Should a female subject become sexually active, she must have agreed to use a double-barrier method or barrier plus spermicide. A woman of childbearing potential was defined as any female who was less than 2 years post-menopausal or had not undergone a hysterectomy or surgical sterilization, e.g., bilateral tubal ligation or bilateral ovariectomy (oophorectomy). Females who were post-menopausal were confirmed by the follicle stimulating hormone (FSH) test at initial screening. * Subjects with a positive urine drug screen for opioids, cocaine, amphetamines, methadone, marijuana, barbiturates, benzodiazepines, methamphetamine, phencyclidine, or tricyclic antidepressants unless the positive screen was determined to be secondary to an allowable concomitant medication. * Subjects with epilepsy or other seizure disorders, Parkinson's disease, or dementia. * Subjects taking bupropion, chlorpheniramine, cimetidine, clomipramine, doxepin, or quinidine within the last 30 days prior to study screening. * Subjects taking clozapine, phenothiazines, aripiprazole, or haloperidol within the last 30 days prior to study screening. * Subjects taking serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine) within the last 30 days prior to study screening. * Subjects taking medications, in addition to those listed above, which may have been expected to significantly interfere with the metabolism or excretion of risperidone and/or 9-hydroxyrisperidone that may have been associated with a significant drug interaction with risperidone, or may have posed a significant risk to subjects' participation in the study. * Subjects who had been previously injected with RBP-7000 in this study. Subjects who were unable, in the opinion of the PI, to comply fully with the study requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] after a subcutaneous injection of a single 60 mg, 90 mg, and 120 mg dose of risperidone in RBP-7000 in subjects with clinically stable schizophrenia | Day 1 through Day 85 | Adverse events, serious adverse events, and discontinuations due to AEs related to treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum plasma concentration (Cmax) of risperidone and total risperidone | Day 0 through Day 85 | Blood samples for PK were collected and analyzed for concentration data of risperidone, 9-hydroxyrisperidone, and total risperidone throughout the study period |
| Time of occurrence of Cmax (Tmax) of risperidone and total risperidone | Day 0 through time of last quantifiable concentration | Blood samples for PK were collected and analyzed for concentration-time data of risperidone, 9-hydroxyrisperidone, and total risperidone throughout the study period |
| Area under the plasma concentration versus time curve (AUC) | Day 0 through Day 85 | Area under the risperidone and total risperidone plasma concentration-time curves from time-zero to Day 85 |
| Observed terminal rate constant of risperidone and total risperidone (λz) | Day 0 through Day 85 | λz estimated by linear regression through at least 3 data points in the terminal phase of the log concentration-time profile |
| Terminal half-life of risperidone and total risperidone (T1/2) | Day 0 through Day 85 | The observed terminal half-life of risperidone, 9-hydroxyrisperidone, and total risperidone was calculated |
Countries
United States
Outcome results
None listed